Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

Anne E. Bras; Zgjim Osmani; Valerie de Haas; Mojca Jongen-Lavrencic; Jeroen G. te Marvelde; C. Michel Zwaan; Ester Mejstrikova; Paula Fernandez; Tomasz Szczepanski; Alberto Orfao; Jacques J.M. van Dongen; Vincent H.J. van der Velden

doi:10.1111/bjh.17210

Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

Anne E. Bras, Zgjim Osmani, Valerie de Haas, Mojca Jongen-Lavrencic, Jeroen G. te Marvelde, C. Michel Zwaan, Ester Mejstrikova, Paula Fernandez, Tomasz Szczepanski, Alberto Orfao, Jacques J.M. van Dongen, Vincent H.J. van der Velden^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

4 Downloads (Pure)

Abstract

Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

Original language	English
Pages (from-to)	922-927
Number of pages	6
Journal	British Journal of Haematology
Volume	193
Issue number	5
Early online date	7 Nov 2020
DOIs	https://doi.org/10.1111/bjh.17210
Publication status	Published - Jun 2021

Bibliographical note

Funding Information:
We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co‐ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6‐2004‐LIFESCIHEALTH‐5 programme of the European Commission (grant LSHB‐CT‐2006‐018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato‐Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA).

Funding Information:
We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co-ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA).

Publisher Copyright:
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Access to Document

10.1111/bjh.17210Licence: CC BY-NC-ND

Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemiaFinal published version, 985 KBLicence: CC BY-NC-ND

Cite this

Bras, A. E., Osmani, Z., de Haas, V., Jongen-Lavrencic, M., te Marvelde, J. G., Zwaan, C. M., Mejstrikova, E., Fernandez, P., Szczepanski, T., Orfao, A., van Dongen, J. J. M., & van der Velden, V. H. J. (2021). Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia. British Journal of Haematology, 193(5), 922-927. https://doi.org/10.1111/bjh.17210

@article{0d40effae5d3479292737d7ec8ddcc20,

title = "Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia",

abstract = "Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.",

author = "Bras, {Anne E.} and Zgjim Osmani and {de Haas}, Valerie and Mojca Jongen-Lavrencic and {te Marvelde}, {Jeroen G.} and Zwaan, {C. Michel} and Ester Mejstrikova and Paula Fernandez and Tomasz Szczepanski and Alberto Orfao and {van Dongen}, {Jacques J.M.} and {van der Velden}, {Vincent H.J.}",

note = "Funding Information: We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co‐ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6‐2004‐LIFESCIHEALTH‐5 programme of the European Commission (grant LSHB‐CT‐2006‐018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato‐Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA). Funding Information: We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co-ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA). Publisher Copyright: {\textcopyright} 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2021",

month = jun,

doi = "10.1111/bjh.17210",

language = "English",

volume = "193",

pages = "922--927",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

AU - Bras, Anne E.

AU - Osmani, Zgjim

AU - de Haas, Valerie

AU - Jongen-Lavrencic, Mojca

AU - te Marvelde, Jeroen G.

AU - Zwaan, C. Michel

AU - Mejstrikova, Ester

AU - Fernandez, Paula

AU - Szczepanski, Tomasz

AU - Orfao, Alberto

AU - van Dongen, Jacques J.M.

AU - van der Velden, Vincent H.J.

N1 - Funding Information: We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co‐ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6‐2004‐LIFESCIHEALTH‐5 programme of the European Commission (grant LSHB‐CT‐2006‐018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato‐Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA). Funding Information: We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co-ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA). Publisher Copyright: © 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

PY - 2021/6

Y1 - 2021/6

N2 - Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

AB - Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

UR - http://www.scopus.com/inward/record.url?scp=85096637278&partnerID=8YFLogxK

U2 - 10.1111/bjh.17210

DO - 10.1111/bjh.17210

M3 - Article

C2 - 33161592

AN - SCOPUS:85096637278

SN - 0007-1048

VL - 193

SP - 922

EP - 927

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this